Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 1809 | 359.34 |
09:39 ET | 150 | 358.17 |
09:41 ET | 100 | 358.195 |
09:43 ET | 113 | 357.53 |
09:50 ET | 700 | 356.795 |
09:54 ET | 100 | 356.175 |
09:56 ET | 600 | 356.175 |
09:57 ET | 400 | 357.16 |
09:59 ET | 700 | 357.16 |
10:01 ET | 100 | 357.16 |
10:03 ET | 326 | 358.345 |
10:08 ET | 800 | 356.95 |
10:10 ET | 100 | 357.6899 |
10:12 ET | 229 | 357.22 |
10:14 ET | 100 | 357.677 |
10:15 ET | 100 | 356.76 |
10:17 ET | 100 | 357.42 |
10:19 ET | 100 | 356.805 |
10:24 ET | 1415 | 357.11 |
10:26 ET | 1590 | 358.05 |
10:32 ET | 100 | 357.52 |
10:33 ET | 100 | 357.39 |
10:35 ET | 574 | 357.325 |
10:37 ET | 200 | 357.26 |
10:42 ET | 1635 | 357.41 |
10:46 ET | 111 | 357.86 |
10:50 ET | 400 | 356.85 |
10:53 ET | 100 | 357.01 |
10:55 ET | 300 | 356.5 |
10:57 ET | 200 | 356.54 |
11:00 ET | 300 | 356.626 |
11:04 ET | 100 | 356.68 |
11:08 ET | 100 | 355.89 |
11:15 ET | 750 | 354.7325 |
11:18 ET | 1981 | 355.265 |
11:22 ET | 200 | 355.305 |
11:24 ET | 200 | 355.62 |
11:26 ET | 100 | 355.29 |
11:27 ET | 100 | 354.93 |
11:31 ET | 400 | 355.18 |
11:42 ET | 200 | 355.015 |
11:45 ET | 1264 | 355.405 |
11:51 ET | 937 | 355.25 |
11:54 ET | 200 | 355.9 |
12:00 ET | 100 | 356.29 |
12:03 ET | 100 | 356.39 |
12:12 ET | 140 | 356.275 |
12:23 ET | 265 | 356.52 |
12:25 ET | 100 | 356.22 |
12:27 ET | 100 | 356.24 |
12:34 ET | 747 | 356.27 |
12:36 ET | 140 | 356.23 |
12:41 ET | 200 | 356 |
12:54 ET | 200 | 355.755 |
12:59 ET | 418 | 356.18 |
01:01 ET | 300 | 355.805 |
01:03 ET | 362 | 355.65 |
01:06 ET | 100 | 355.605 |
01:10 ET | 200 | 355.53 |
01:12 ET | 254 | 355.45 |
01:14 ET | 200 | 355.38 |
01:26 ET | 100 | 354.9292 |
01:28 ET | 1010 | 354.435 |
01:30 ET | 600 | 354.51 |
01:32 ET | 308 | 354.62 |
01:33 ET | 818 | 354.65 |
01:37 ET | 452 | 355.095 |
01:39 ET | 100 | 355.095 |
01:44 ET | 100 | 355.18 |
01:46 ET | 100 | 355.25 |
01:48 ET | 300 | 355.175 |
01:50 ET | 100 | 355.255 |
01:53 ET | 300 | 355.43 |
01:57 ET | 1100 | 355.42 |
02:00 ET | 730 | 355.4037 |
02:04 ET | 300 | 355.49 |
02:06 ET | 100 | 355.68 |
02:08 ET | 100 | 355.75 |
02:09 ET | 100 | 355.9 |
02:13 ET | 200 | 355.9 |
02:15 ET | 300 | 356.22 |
02:18 ET | 394 | 356.02 |
02:20 ET | 400 | 356.48 |
02:22 ET | 200 | 356.67 |
02:24 ET | 135 | 356.67 |
02:31 ET | 200 | 356.645 |
02:33 ET | 103 | 356.895 |
02:36 ET | 200 | 356.895 |
02:38 ET | 217 | 356.81 |
02:45 ET | 140 | 356.605 |
02:51 ET | 400 | 356.35 |
02:58 ET | 200 | 356.335 |
03:00 ET | 1730 | 356.13 |
03:02 ET | 400 | 356.01 |
03:03 ET | 211 | 356.17 |
03:05 ET | 200 | 356.23 |
03:07 ET | 301 | 356.2 |
03:09 ET | 200 | 356.46 |
03:12 ET | 200 | 356.68 |
03:20 ET | 200 | 356.48 |
03:21 ET | 100 | 356.675 |
03:25 ET | 405 | 356.8801 |
03:27 ET | 200 | 357.19 |
03:30 ET | 239 | 357.2676 |
03:32 ET | 200 | 357.31 |
03:36 ET | 441 | 357.02 |
03:38 ET | 392 | 357.0252 |
03:41 ET | 200 | 356.99 |
03:45 ET | 935 | 356.3097 |
03:48 ET | 1307 | 356.345 |
03:50 ET | 500 | 356.81 |
03:52 ET | 900 | 356.5629 |
03:54 ET | 200 | 356.77 |
03:56 ET | 867 | 357.33 |
03:57 ET | 3344 | 357.99 |
03:59 ET | 49934 | 357.96 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 15.9B | 16.5x | +8.22% |
Biomarin Pharmaceutical Inc | 13.4B | 52.8x | --- |
Exact Sciences Corp | 12.6B | -70.8x | --- |
Neurocrine Biosciences Inc | 11.6B | 34.5x | +62.04% |
Qiagen NV | 10.2B | 141.1x | +12.66% |
Medpace Holdings Inc | 10.3B | 31.4x | +35.10% |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.9B |
---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $21.75 |
Book Value | $127.23 |
P/E Ratio | 16.5x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | 14.1x |
Operating Margin | 48.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.